Carbon Quantum Dots For Drug Delivery: Advanced Synthesis, Functionalization Strategies, And Biomedical Applications

Molecular Composition And Structural Characteristics Of Carbon Quantum Dots For Drug Delivery

Carbon quantum dots represent a unique class of quasi-spherical carbon nanoparticles with discrete structures typically ranging from 2 to 10 nm in diameter 1. The core architecture consists of sp²-hybridized carbon domains forming graphitic or amorphous carbon frameworks, surrounded by abundant surface functional groups including carboxyl (-COOH), hydroxyl (-OH), amino (-NH₂), and carbonyl (C=O) moieties 9. These surface functionalities are critical for drug loading, colloidal stability in physiological environments, and subsequent bioconjugation strategies 2.

The chemical composition of CQDs extends beyond pure carbon, frequently incorporating heteroatoms such as nitrogen, oxygen, sulfur, and phosphorus either through precursor selection or post-synthetic doping 9. For drug delivery applications, nitrogen-doped CQDs exhibit enhanced quantum yields and positive surface charges that facilitate electrostatic interactions with negatively charged cell membranes and nucleic acids 11. The graphitic core provides structural rigidity and optical activity, while the functionalized shell enables covalent or non-covalent drug conjugation through π-π stacking, hydrogen bonding, or electrostatic interactions 4.

X-ray diffraction (XRD) analysis typically reveals a broad diffraction peak around 2θ = 20–25°, corresponding to the (002) plane of graphitic carbon with an interlayer spacing of approximately 0.34–0.36 nm 9. Transmission electron microscopy (TEM) confirms the monodisperse nature of synthesized CQDs, with particle size distributions that can be controlled through synthesis parameters such as reaction temperature (120–250°C for hydrothermal methods), precursor concentration, and reaction duration (2–24 hours) 5. Fourier-transform infrared spectroscopy (FTIR) provides detailed information on surface functional groups, with characteristic absorption bands at 3200–3600 cm⁻¹ (O-H/N-H stretching), 1650–1750 cm⁻¹ (C=O stretching), and 1000–1300 cm⁻¹ (C-O stretching) 9.

The optical properties of CQDs are governed by quantum confinement effects and surface states, exhibiting excitation-wavelength-dependent photoluminescence with emission maxima typically in the blue-green region (400–550 nm) 1. Fluorescence quantum yields vary significantly based on synthesis method and surface passivation, with boronic acid-functionalized CQDs achieving quantum yields exceeding 40% and demonstrating superior photostability against photobleaching compared to conventional organic dyes 1. UV-visible absorption spectra show characteristic peaks around 230–270 nm (π-π* transitions of aromatic C=C bonds) and 300–350 nm (n-π* transitions of C=O bonds), providing multiple excitation pathways for bioimaging applications 9.

Synthesis Routes And Preparation Methods For Carbon Quantum Dots In Drug Delivery Systems

Top-Down Synthesis Approaches

Top-down methodologies involve the fragmentation of bulk carbon materials into nanoscale CQDs through physical or chemical processes 1. Laser ablation represents a rapid synthesis route where high-energy laser pulses (typically Nd:YAG lasers at 532 nm or 1064 nm, pulse duration 5–10 ns, energy density 50–200 mJ/cm²) irradiate carbon targets (graphite, carbon black, or carbon nanotubes) in liquid media 1. This technique produces CQDs with narrow size distributions (3–5 nm) and high crystallinity within minutes, though equipment costs remain substantial 1.

Electrochemical exfoliation offers a scalable alternative, employing graphite electrodes in electrolyte solutions (0.1–0.5 M H₂SO₄, NaOH, or phosphate buffers) under applied potentials of 3–10 V for 2–12 hours 13. The electrochemical process generates oxygen-containing functional groups that facilitate exfoliation and subsequent fragmentation into CQDs with diameters of 2–8 nm 13. Acidic oxidation methods utilize strong oxidizing agents (concentrated H₂SO₄/HNO₃ mixtures at volume ratios of 3:1, refluxed at 80–120°C for 6–24 hours) to cleave carbon powder or graphite into CQDs 2. This approach yields highly functionalized CQDs with abundant carboxyl groups suitable for drug conjugation, though extensive purification via dialysis (molecular weight cut-off 500–1000 Da, 48–72 hours) is required to remove residual acids 2.

Bottom-Up Synthesis Strategies

Bottom-up approaches construct CQDs from molecular precursors through carbonization and nucleation processes, offering superior control over size, composition, and surface chemistry 1. Hydrothermal synthesis represents the most widely adopted method, involving the thermal treatment of organic precursors (citric acid, glucose, amino acids, or natural extracts) in aqueous solutions at 120–250°C for 2–24 hours in sealed autoclaves 59. For example, citric acid (1–10 g/L) combined with ethylenediamine (molar ratio 1:1 to 1:4) at 180°C for 6 hours produces nitrogen-doped CQDs with quantum yields of 60–80% and particle sizes of 3–6 nm 11.

Microwave-assisted synthesis accelerates carbonization through rapid volumetric heating, reducing reaction times to 2–10 minutes while maintaining comparable product quality 9. A representative protocol involves dissolving Ferula Asafoetida extract (5 g/L) in deionized water and subjecting the solution to microwave irradiation (700 W, 5 minutes), yielding blue-luminescent CQDs (quantum yield ~45%, diameter 4–7 nm) without post-treatment 9. The hot bubble method, a recent innovation, employs controlled bubble formation during thermal treatment to enhance mass transfer and produce CQDs with improved optical properties 5.

Solvothermal synthesis extends hydrothermal principles to non-aqueous solvents (ethanol, dimethylformamide, or ionic liquids), enabling the incorporation of hydrophobic functional groups and expanding the range of compatible drug molecules 1. Plasma treatment and thermal decomposition represent alternative routes, though their application in drug delivery remains limited due to challenges in controlling surface functionalization 1.

Functionalization And Surface Modification For Drug Loading

Post-synthetic modification is essential for tailoring CQD properties to specific drug delivery requirements 4. Covalent conjugation strategies exploit surface carboxyl groups through carbodiimide chemistry (EDC/NHS coupling) to attach amine-containing drugs or targeting ligands 2. For instance, large amino acid-mimicking CQDs (LAAM-CQDs) are synthesized by conjugating polycyclic aromatic compounds substituted with amino and carboxylic acid groups, resulting in nanoparticles with selective affinity for LAT1-expressing tumor cells 412.

Boronic acid functionalization enhances photostability and enables reversible binding to diol-containing drugs or glycoproteins 1. Polyethylenimine (PEI) coating generates cationic CQDs (CCDs) suitable for nucleic acid delivery, with surface modification achieved by stirring anionic CQDs (derived from citric acid hydrothermal treatment) with branched PEI (molecular weight 1.8–25 kDa) at mass ratios of 1:1 to 1:5 for 12–24 hours at room temperature 11. Porphyrin conjugation produces CQDs with enhanced singlet oxygen generation capacity for photodynamic therapy, synthesized through one-pot reactions of porphyrin derivatives with carbon precursors under hydrothermal conditions (160–200°C, 8–12 hours) 10.

Physicochemical Properties And Performance Characteristics For Drug Delivery Applications

Optical Properties And Imaging Capabilities

The photoluminescence properties of CQDs are fundamental to their utility in theranostic applications, enabling simultaneous drug delivery monitoring and therapeutic efficacy assessment 36. CQDs exhibit broad absorption spectra spanning UV to visible regions (250–500 nm) and tunable emission wavelengths (400–700 nm) dependent on excitation wavelength, particle size, surface states, and heteroatom doping 9. Quantum yields vary from 5% for undoped CQDs to 80% for optimally passivated nitrogen-doped variants, with boronic acid-functionalized CQDs demonstrating quantum yields ≥40% and exceptional resistance to photobleaching under continuous UV irradiation (365 nm, 10 mW/cm², >24 hours) 1.

The excitation-dependent emission behavior arises from multiple emissive sites including quantum confinement effects in the sp² carbon core, surface defect states, and molecular fluorophores on the CQD periphery 9. This property enables multicolor imaging by simply varying excitation wavelengths, facilitating multiplexed tracking of different drug-CQD conjugates within biological systems 7. Time-resolved fluorescence measurements reveal excited-state lifetimes of 1–15 nanoseconds, suitable for fluorescence lifetime imaging microscopy (FLIM) applications that distinguish CQD signals from autofluorescence 9.

Two-photon absorption cross-sections of CQDs (10²–10⁴ GM, where 1 GM = 10⁻⁵⁰ cm⁴·s·photon⁻¹) enable deep-tissue imaging using near-infrared excitation (700–1000 nm), minimizing photodamage and achieving penetration depths of 200–500 μm in tissue phantoms 3. Light-responsive drug release can be triggered through photothermal conversion, with CQDs exhibiting photothermal conversion efficiencies of 20–40% under 808 nm laser irradiation (0.5–2 W/cm²), generating localized temperature increases of 10–25°C sufficient to disrupt drug-CQD interactions 15.

Drug Loading Mechanisms And Capacity

CQDs accommodate diverse drug molecules through multiple loading mechanisms, with capacity and release kinetics dependent on drug-CQD interaction modes 36. Hydrophobic drugs (log P > 0) such as doxorubicin, paclitaxel, and curcumin are physically entrapped within the CQD surface layer through π-π stacking interactions with aromatic carbon domains and hydrophobic pockets created by surface ligands 36. Loading capacities for hydrophobic drugs typically range from 15% to 45% (w/w drug/CQD), determined by equilibrium dialysis or ultracentrifugation methods 6.

Covalent conjugation via amide, ester, or disulfide bonds provides stable drug attachment for systemic circulation, with loading efficiencies of 5–20% (w/w) depending on available surface functional groups (typically 2–8 mmol/g carboxyl groups for citric acid-derived CQDs) 2. Electrostatic adsorption is particularly effective for charged therapeutics, with cationic CQDs (ζ-potential +15 to +40 mV) binding anionic drugs or nucleic acids at loading ratios of 10–30% (w/w) 11. The large surface-to-volume ratio of CQDs (calculated as 6/d for spherical particles, yielding 600–3000 m²/g for 2–10 nm particles) maximizes drug-nanoparticle contact area 1.

Drug release kinetics are governed by environmental stimuli including pH, temperature, light, and enzymatic activity 3615. pH-responsive release exploits the protonation/deprotonation of surface functional groups, with accelerated release in acidic tumor microenvironments (pH 5.5–6.5) compared to physiological pH (7.4) 2. Light-triggered release occurs through photochemical bond cleavage or photothermal heating, with release rates controllable by light intensity (0.1–2 W/cm²) and duration (seconds to minutes) 36. Sustained release profiles over 24–72 hours are achievable through optimization of drug-CQD binding strength and surface coating with biocompatible polymers 8.

Biocompatibility And Toxicity Profiles

The biocompatibility of CQDs is a critical advantage over traditional semiconductor quantum dots containing cadmium, lead, or mercury 19. In vitro cytotoxicity assays (MTT, CCK-8, or LDH release) demonstrate cell viabilities >80% at CQD concentrations up to 100–500 μg/mL across multiple cell lines (HeLa, HepG2, MCF-7, NIH-3T3) after 24–72 hour incubation 9. Hemolysis assays show <5% red blood cell lysis at concentrations up to 1 mg/mL, indicating excellent hemocompatibility 9.

In vivo toxicity studies in rodent models reveal no significant adverse effects at doses up to 20 mg/kg body weight administered intravenously or intraperitoneally 412. Histopathological examination of major organs (liver, kidney, spleen, heart, lung) shows no inflammation, necrosis, or structural abnormalities after 7–30 days post-administration 12. Blood biochemistry parameters (alanine aminotransferase, aspartate aminotransferase, creatinine, blood urea nitrogen) remain within normal ranges, confirming hepatic and renal safety 12.

Biodistribution studies using fluorescence imaging demonstrate preferential accumulation in reticuloendothelial organs (liver, spleen) with clearance half-lives of 2–8 hours for small CQDs (<5 nm) primarily via renal excretion, and 12–48 hours for larger CQDs (>5 nm) cleared through hepatobiliary pathways 12. Surface functionalization with polyethylene glycol (PEG, molecular weight 2–5 kDa) extends circulation time to 6–24 hours by reducing opsonization and macrophage uptake 4. Long-term toxicity assessments (90 days) show no evidence of chronic inflammation, organ damage, or behavioral abnormalities in treated animals 12.

Genotoxicity evaluations including Ames tests, micronucleus assays, and comet assays indicate no mutagenic or DNA-damaging effects at concentrations up to 500 μg/mL 7. However, certain CQD formulations designed for cancer therapy intentionally generate oxidative stress through reactive oxygen species (ROS) production, causing mitochondrial dysfunction and dose-dependent genotoxicity specifically in tumor cells 7. This selective toxicity is exploited for anticancer applications while sparing normal cells 7.

Targeted Drug Delivery Strategies Using Carbon Quantum Dots

Passive Targeting Through Enhanced Permeability And Retention Effect

CQDs exploit the enhanced permeability and retention (EPR) effect characteristic of solid tumors, where fenestrated vasculature (pore sizes 100–800 nm) and impaired lymphatic drainage enable preferential accumulation of nanoparticles 412. Optimal CQD sizes for EPR-mediated targeting range from 5 to 50 nm, with circulation times extended through PEGylation or albumin coating 4. Biodistribution studies demonstrate 2–5-fold higher tumor accumulation compared to normal tissues at 24–48 hours post-injection, with tumor-to-muscle ratios reaching 8:1 for optimized formulations 12.

Active Targeting Via Receptor-Mediated Endocytosis

Active targeting strategies conjugate CQDs with ligands recognizing overexpressed tumor receptors, achieving enhanced cellular uptake and specificity 412. Large amino acid transporter 1 (LAT1)-targeting CQDs, synthesized by incorporating large amino acid-mimicking compounds (e.g., tyrosine, phenylalanine derivatives), demonstrate selective internalization in LAT1-overexpressing cancer cells (glioblastoma, melanoma, lung cancer) with 5–10-fold higher uptake compared to LAT1